Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Combined analysis of IGHV mutations, telomere length and CD49d identifies long-term progression-free survivors in TP53 wild-type CLL treated with FCR-based therapies.
Pepper AGS, Zucchetto A, Norris K, Tissino E, Polesel J, Soe Z, Allsup D, Hockaday A, Ow PL, Hillmen P, Rawstron A, Catovsky D, Bulian P, Bomben R, Baird DM, Fegan CD, Gattei V, Pepper C. Pepper AGS, et al. Among authors: hockaday a. Leukemia. 2022 Jan;36(1):271-274. doi: 10.1038/s41375-021-01322-1. Epub 2021 Jun 19. Leukemia. 2022. PMID: 34148055 Free PMC article. No abstract available.
Results of the randomized phase IIB ADMIRE trial of FCR with or without mitoxantrone in previously untreated CLL.
Munir T, Howard DR, McParland L, Pocock C, Rawstron AC, Hockaday A, Varghese A, Hamblin M, Bloor A, Pettitt A, Fegan C, Blundell J, Gribben JG, Phillips D, Hillmen P. Munir T, et al. Among authors: hockaday a. Leukemia. 2017 Oct;31(10):2085-2093. doi: 10.1038/leu.2017.65. Epub 2017 Apr 20. Leukemia. 2017. PMID: 28216660 Free article. Clinical Trial.
Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trial.
Collett L, Howard DR, Munir T, McParland L, Oughton JB, Rawstron AC, Hockaday A, Dimbleby C, Phillips D, McMahon K, Hulme C, Allsup D, Bloor A, Hillmen P. Collett L, et al. Among authors: hockaday a. Trials. 2017 Aug 22;18(1):387. doi: 10.1186/s13063-017-2138-6. Trials. 2017. PMID: 28830517 Free PMC article. Clinical Trial.
Trial re-investment to build better research for better impact.
Fox TA, Horne GA, Craddock C, Cook G, O'Brien S, Fox S, Hockaday A, Silk G, Hillmen P. Fox TA, et al. Among authors: hockaday a. Lancet. 2019 Aug 24;394(10199):635-636. doi: 10.1016/S0140-6736(19)31363-7. Lancet. 2019. PMID: 31448733 Free article. No abstract available.
COSMIC, chemotherapy plus ofatumumab at standard or mega-dose in chronic lymphocytic leukaemia, a phase II randomised study.
Allsup D, Howard D, Emmerson J, Hockaday A, Rawstron A, Oughton JB, Bloor A, Phillips D, Nathwani A, Paneesha S, Turner D, Munir T, Hillmen P. Allsup D, et al. Among authors: hockaday a. Br J Haematol. 2021 Aug;194(3):646-650. doi: 10.1111/bjh.17526. Epub 2021 May 24. Br J Haematol. 2021. PMID: 34028800 Clinical Trial. No abstract available.
TP53 Mutations with Low Variant Allele Frequency Predict Short Survival in Chronic Lymphocytic Leukemia.
Bomben R, Rossi FM, Vit F, Bittolo T, D'Agaro T, Zucchetto A, Tissino E, Pozzo F, Vendramini E, Degan M, Zaina E, Cattarossi I, Varaschin P, Nanni P, Berton M, Braida A, Polesel J, Cohen JA, Santinelli E, Biagi A, Gentile M, Morabito F, Fronza G, Pozzato G, D'Arena G, Olivieri J, Bulian P, Pepper C, Hockaday A, Schuh A, Hillmen P, Rossi D, Chiarenza A, Zaja F, Di Raimondo F, Del Poeta G, Gattei V. Bomben R, et al. Among authors: hockaday a. Clin Cancer Res. 2021 Oct 15;27(20):5566-5575. doi: 10.1158/1078-0432.CCR-21-0701. Epub 2021 Jul 20. Clin Cancer Res. 2021. PMID: 34285062 Free article.
53 results